Natera CFO Michael Burkes sells $115,661 in company stock

AUSTIN, TX—Brophy Michael Burkes, the Chief Financial Officer of Natera, Inc. (NASDAQ:NTRA), recently executed a sale of company stock valued at $115,661. The transactions, which took place on March 17, involved the sale of 792 shares of common stock at prices ranging from $146.0277 to $149.575 per share. The sale comes as Natera’s stock has shown remarkable strength, delivering a 62.4% return over the past year, with the company now commanding a market capitalization of $20.41 billion. According to InvestingPro analysis, the stock currently trades above its Fair Value.

The stock sales were conducted to meet tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). These transactions were made following a pre-established trading plan intended to comply with Rule 10b5-1 under the Securities Exchange Act. InvestingPro data indicates the stock has exhibited notable volatility, with 11 additional key insights available to subscribers.

Following these sales, Burkes retains ownership of 71,869 shares of Natera’s common stock. The company maintains strong financial health with a current ratio of 4.0 and operates with a moderate debt level, as indicated by its debt-to-equity ratio of 0.16.

In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with a revenue of $476 million, a 53% increase year-over-year, and a narrower-than-anticipated loss per share of -$0.41. Despite these strong financial results, the company’s stock experienced a decline during regular trading hours. Analysts from TD Cowen and Canaccord Genuity have maintained a Buy rating on Natera, with both firms setting a price target of $195, citing robust future sales projections and potential growth in gross margins as key factors. The company’s guidance for 2025 indicates a projected revenue growth of 24% at the midpoint, with expectations of continued strong gross margins and positive cash flow.

In other developments, Natera has initiated the HEROES clinical trial to explore therapy de-escalation in metastatic HER2+ breast cancer patients, funded by the French Ministry of Health. This trial aims to assess the feasibility of using ctDNA-guided treatment to potentially reduce or stop therapy in patients without detectable molecular disease. Additionally, Natera has received positive feedback from the scientific community on its recent clinical data, particularly in colorectal cancer, which could influence future guidelines and adoption rates. These recent developments highlight Natera’s ongoing efforts to expand its clinical offerings and enhance its market position in genetic testing and diagnostics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.